Status:
UNKNOWN
Development of Multimodal Fusion Warning System and Non-invasive Techniques for Early Alzheimer's Detection.
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55-80 years
Phase:
NA
Brief Summary
Developing and validating an early digitalized recognition device and multimodal warning model for Alzheimer's disease, and establishing a precision transcranial ultrasound stimulation intervention sy...
Detailed Description
1. Establishment of early digitalized recognition devices and multimodal warning models for AD: Participants undergo clinical assessments, and if they meet the inclusion criteria, their gender, age, M...
Eligibility Criteria
Inclusion
- Patients diagnosed with MCI / AD
- Between the ages of 55 and 80
- No history of mental illness such as schizophrenia, severe anxiety and depression
Exclusion
- Consistent with Parkinson's disease, frontotemporal dementia, dementia with lewy bodies Or Huntington's disease diagnostic criteria
- Dementia due to other causes (e.g. cerebrovascular disease, central nervous system trauma, tumors, infections, Metabolic diseases, normal stress hydrocephalus, folic acid or vitamin B12 deficiency, hypothyroidism, etc.)
- Have aphasia,Disorders that affect cognitive assessment, such as disorders of consciousness
- Have a history of epilepsy or take antiepileptic drugs
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05978830
Start Date
March 1 2022
End Date
December 30 2024
Last Update
August 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yi Ling
Hangzhou, Zhejiang, China, 310000